https://dnasynthesis-signal.co....m/index.php/availabl
Biogen's pharmacovigilance systems were used to retrospectively analyze patient backgrounds, risk factors, medical characteristics, and treatment outcomes for verified natalizumab-associated EID and SID PML cases. From a dataset of 857 confirmed natalizumab-induced PML cases, 75% were categorized as EID and 925% were SID. The breakdown in the US was 129% for EID and 871% for SID, whereas the ROW saw 54% and 946%, respe